Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.
Ofran Y, Leiba R, Ganzel C, Saban R, Gatt M, Ram R, Arad A, Bulvik S, Hellmann I, Gino-Moor S, Zuckerman T, Hoffman R, Horowitz N, Lavi N, Ringelstein S, Henig I, Hayun M, Rowe JM. Ofran Y, et al. Among authors: leiba r. Am J Hematol. 2015 Dec;90(12):1159-64. doi: 10.1002/ajh.24207. Epub 2015 Nov 17. Am J Hematol. 2015. PMID: 26435038 Free article.
Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.
Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C. Ofran Y, et al. Among authors: leiba r. Am J Hematol. 2020 Jan;95(1):E3-E5. doi: 10.1002/ajh.25651. Epub 2019 Oct 17. Am J Hematol. 2020. PMID: 31591736 Free article. No abstract available.
Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers.
Hussein K, Dabaja-Younis H, Szwarcwort-Cohen M, Almog R, Leiba R, Weissman A, Mekel M, Hyams G, Horowitz NA, Gepstein V, Cohen Saban H, Tarabeia J, Halberthal M, Shachor-Meyouhas Y. Hussein K, et al. Among authors: leiba r. Vaccines (Basel). 2022 Oct 18;10(10):1741. doi: 10.3390/vaccines10101741. Vaccines (Basel). 2022. PMID: 36298606 Free PMC article.
Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers.
Shachor-Meyouhas Y, Dabaja-Younis H, Magid A, Leiba R, Szwarcwort-Cohen M, Almog R, Mekel M, Weissman A, Hyams G, Gepstein V, Horowitz NA, Cohen Saban H, Tarabeia J, Halberthal M, Hussein K. Shachor-Meyouhas Y, et al. Among authors: leiba r. Vaccines (Basel). 2023 Jan 28;11(2):283. doi: 10.3390/vaccines11020283. Vaccines (Basel). 2023. PMID: 36851161 Free PMC article.
Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Henig I, Isenberg J, Yehudai-Ofir D, Leiba R, Ringelstein-Harlev S, Ram R, Avni B, Amit O, Grisariu S, Azoulay T, Slouzkey I, Zuckerman T. Henig I, et al. Among authors: leiba r. Vaccines (Basel). 2023 Mar 31;11(4):775. doi: 10.3390/vaccines11040775. Vaccines (Basel). 2023. PMID: 37112688 Free PMC article.
49 results